Summarized by Masters of Longevity from Longevity Technology.
HexemBio’s fundraising and pipeline are presented in a biotech feature explaining its approach to rejuvenating aging blood stem cells and therapeutic directions.
Key Takeaways
- HexemBio raised $15.5 million with new investor Happiness Capital joining Draper Associates and Boost VC.
- The company published its Synthetic Human Yolk Sac platform in Nature and has 17 patent applications with two granted.
- The lead transplant cell-therapy received Orphan Drug Designation and completed a pre-IND meeting with the FDA targeting first-in-human trials in 2027.
